Hypoglossal Nerve Stimulation for Down Syndrome Sleep Apnea
Hypoglossal Nerve Stimulation Shows Promise for Children with Down Syndrome and Sleep Apnea
Obstructive sleep apnea (OSA) is a common and serious condition, especially affecting individuals with Down syndrome. A recent study published in the International Journal of Pediatric Otorhinolaryngology offers significant hope, demonstrating the safety and efficacy of hypoglossal nerve stimulation (HNS) surgery for children with Down syndrome under the age of 13. This innovative treatment shows remarkable reductions in sleep apnea events and coudl pave the way for FDA approval for younger patients.
Understanding Sleep Apnea in Children with Down Syndrome
Children with down syndrome are disproportionately affected by OSA due to anatomical differences, including smaller upper airways and reduced muscle tone. OSA causes repeated interruptions in breathing during sleep, leading to daytime sleepiness, behavioral problems, impaired cognitive progress, and potential long-term cardiovascular complications. Traditional treatments, such as adenotonsillectomy (removal of the adenoids and tonsils), are often insufficient, and continuous positive airway pressure (CPAP) can be poorly tolerated in children.
Breakthrough Study: Safety and Efficacy of Hypoglossal Nerve Stimulation
Researchers at Mass Eye and Ear, in collaboration with clinicians at Massachusetts General Hospital specializing in Down syndrome and pediatric sleep medicine, conducted a study involving 29 children with Down syndrome who underwent HNS surgery. The procedure involves implanting a small device that stimulates the hypoglossal nerve, which controls tongue movement, keeping the airway open during sleep.
Key Findings:
Safety: The surgery was deemed safe in all participants, with only one minor adverse event related to wound healing. No adverse events were linked to the device itself. Crucially, the device remained stable over a three-year follow-up period, addressing concerns about growth-related complications.
Significant Reduction in Sleep Apnea: Children experienced dramatic improvements in their sleep apnea. At six months post-surgery,over 95% showed a reduction of 50% or more in their Apnea-hypopnea Index (AHI) - a measure of sleep apnea severity. The median AHI decreased from over 18 events per hour before surgery to nearly 4 events per hour afterward.
Long-Term Monitoring: Sleep studies were performed before surgery and then at 1 to 3 months, 6 months, 1 year, and 3 years after surgery, providing valuable long-term data on the treatment’s durability.
Implications for Treatment and Future Research
This research has several critically important implications.First, it alleviates concerns about the safety of HNS in young children, a population previously considered too young for this intervention. The long-term stability of the implant as children grow is particularly reassuring.
Second, the positive results provide compelling data for submission to the Food and Drug administration (FDA) to seek approval for HNS as a treatment option for younger children with Down syndrome and OSA.
Beyond the clinical implications, the study offers hope to parents who have worried about their children’s sleep apnea and its potential impact on their development and quality of life.
Next Steps in Research:
the research team is actively pursuing further studies to investigate the broader benefits of early HNS treatment. current and planned research includes:
Neurocognitive Impact: researchers are seeking funding to determine if earlier treatment with HNS leads to greater improvements in neurocognition for children with Down syndrome.
Longitudinal Study in Younger Children: Building on a previous trial in teens and young adults, the team aims to conduct a similar study focusing on children aged 4-10. This study will be supported by a five-year grant from the National Institutes of Health (NIH).
Qualitative Data Validation: While anecdotal reports from parents suggest improvements in areas like behavior,mood,and speech,the team is committed to gathering data to scientifically validate these observations.
This research represents a significant step forward in the treatment of OSA in children with Down syndrome, offering a potentially life-changing solution for a vulnerable population.Source:
kim, M., et al. (2025). Hypoglossal nerve stimulator for obstructive sleep apnea in children with down syndrome younger than 13. International Journal of Pediatric Otorhinolaryngology. doi.org/10.1016/j.ijporl.2025.112497